WhiteNest Pharma announces a pivotal advancement for non-transfusional blood components in Italy, following the Centro Nazionale Sangue’s (CNS) recent clarification on national tariffs, as detailed in their FAQ section. This update directly impacts the use of adult blood allogenic platelets processed with the BioNest 12D system, addressing prior uncertainties in ‘L’Accordo Stato Regioni ASR 90/CRS del 17 June 2021’.
Previously, varied interpretations of the agreement had led to a decrease in requests for non-transfusional use of adult blood allogenic platelets in certain regions, affecting BioNest 12D’s market presence. The CNS publication now clarifies tariff applications for these components, ensuring uniform understanding and reinstating the system’s utilization. Key to this update is the allocation of tariffs per aliquot derived from a parent product, simplifying the cost structure for medical facilities and promoting broader access to these essential treatments.
This clarification is expected to revitalize BioNest 12D’s role in Italian healthcare, facilitating enhanced patient care through the widespread availability of non-transfusional blood components. WhiteNest Pharma looks forward to supporting healthcare providers with this clarified framework, aiming to improve therapeutic outcomes across the region.
The CNS’s initiative in providing clear guidelines marks a significant step forward in the efficient use of blood components for non-transfusional purposes. WhiteNest Pharma is committed to aligning with these directives to ensure the BioNest 12D system continues to contribute to innovative medical treatments in Italy.